Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Surveying clinician practices on MRD utilization for myeloma

Benjamin Derman • 15 Sep 2019
IMW 2019
Multiple Myeloma

Benjamin Derman, MD, from the University of Chicago, Chicago, IL, provides insight on an interesting aspect of MRD utilization – surveying clinician practices to give a more in-depth insight. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Benjamin Derman

The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma 4:26
The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman • 1 Dec 2023
MRD-guided treatment cessation in multiple myeloma 3:43
MRD-guided treatment cessation in multiple myeloma
Benjamin Derman • 1 Dec 2023
Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial 9:57
Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial
Benjamin Derman • 1 Dec 2023
MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd 5:25
MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd
Benjamin Derman • 1 Jun 2022

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals